This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrait, G.
Right arrow Articles by Alric, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrait, G.
Right arrow Articles by Alric, M.
Agricola
Right arrow Articles by Garrait, G.
Right arrow Articles by Alric, M.

 Previous Article  |  Next Article 

Applied and Environmental Microbiology, June 2007, p. 3566-3574, Vol. 73, No. 11
0099-2240/07/$08.00+0     doi:10.1128/AEM.02091-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Recombinant Saccharomyces cerevisiae Strain Expressing a Model Cytochrome P450 in the Rat Digestive Environment: Viability and Bioconversion Activity{triangledown}

G. Garrait, J. F. Jarrige, S. Blanquet, E. Beyssac, and M. Alric*

Université Clermont1, UFR Pharmacie, Centre de Recherche en Nutrition Humaine d'Auvergne, Institut Fédératif de Recherche Santé-Auvergne, Equipe de Recherche Technologique Conception, Ingénierie et Développement de l'Aliment et du Médicament, F-63001 Clermont-Ferrand, France

Received 5 September 2006/ Accepted 2 April 2007

An innovative "biodrug" concept, based on the oral administration of living recombinant microorganisms, has recently emerged for the prevention or treatment of various diseases. An engineered Saccharomyces cerevisiae strain expressing plant P450 73A1 (cinnamate-4-hydroxylase [CA4H] activity) was used, and its survival and ability to convert trans-cinnamic acid (CIN) into p-coumaric acid (COU) were investigated in vivo. In rats, the recombinant yeast was resistant to gastric and small intestinal secretions but was more sensitive to the conditions found in the large intestine. After oral administration of yeast and CIN, the CA4H activity was shown in vivo, with COU being found throughout the rat's digestive tract and in its urine. The bioconversion reaction occurred very fast, with most of the COU being produced within the first 5 min. The gastrointestinal sac technique demonstrated that the recombinant yeast was able to convert CIN into COU (conversion rate ranging from 2 to 5%) in all the organs of the rat's digestive tract: stomach, duodenum, jejunum, ileum, cecum, and colon. These results promise new opportunities for the development of drug delivery systems based on engineered yeasts catalyzing a bioconversion reaction directly in the digestive tract.

* Corresponding author. Mailing address: Equipe de Recherche Technologique Conception, Ingénierie et Développement de l'Aliment et du Médicament (ERT CIDAM), 5 ème Etage, CBRV, Faculté de Pharmacie, Université d'Auvergne, 28 Place Henri-Dunant, 63001 Clermont-Ferrand, France. Phone: 33 473 17 79 52. Fax: 33 473 17 83 92. E-mail: Monique.ALRIC{at}crnh.u-clermont1.fr

{triangledown} Published ahead of print on 6 April 2007.

Applied and Environmental Microbiology, June 2007, p. 3566-3574, Vol. 73, No. 11
0099-2240/07/$08.00+0     doi:10.1128/AEM.02091-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»